We excluded patients with EGFR-mutated or ALK-mutated NSCLC, which are primarily treated with molecularly targeted agents, to investigate the possible influence of kinlessness on the risk management of chemotherapy-related adverse events. This evidence concerns the gene ALK and non-small cell lung carcinoma.